Solid lipid nanoparticles: A potential multifunctional approach towards rheumatoid arthritis theranostics

Molecules

Volumn 20, Issue 6, 2015, Pages 11103-11118

  Albuquerque, João ^a   Moura, Catarina Costa ^a   Sarmento, Bruno ^b,c   Reis, Salette ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b INEB INSTITUTO DE ENGENHARIA BIOMÉDICA   (Portugal)

^c INSTITUTO DE INVESTIGAÇÃO E FORMAÇÃO AVANÇADA EM CIÊNCIAS E TECNOLOGIAS DA SAÚDE   (Portugal)

Author keywords

Nanomedicine; Rheumatoid arthritis; Solid lipid nanoparticles; Theranostics

Indexed keywords

DRUG CARRIER; LIPID; MONOCLONAL ANTIBODY; NANOPARTICLE;

ARTHRITIS, RHEUMATOID; CELL LINE; CHEMISTRY; HUMAN; INFRARED SPECTROSCOPY; MEDICINAL CHEMISTRY; PARTICLE SIZE; THERANOSTIC NANOMEDICINE; ULTRASTRUCTURE;

ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; CELL LINE; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; HUMANS; LIPIDS; NANOPARTICLES; PARTICLE SIZE; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; THERANOSTIC NANOMEDICINE;

EID: 84938265072     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules200611103     Document Type: Article

References (33)

1. Smolen, J.S.; Aletaha, D.; Bijlsma, J.W.; Breedveld, F.C.; Boumpas, D.; Burmester, G.; Combe, B.; Cutolo, M.; de Wit, M.; Dougados, M.; et al. Treating rheumatoid arthritis to target: Recommendations of an international task force. Ann. Rheum. Dis. 2010, 69, 631-637.
2. Choy, E.H.; Kavanaugh, A.F.; Jones, S.A. The problem of choice: Current biologic agents and future prospects in RA. Nat. Rev. Rheumatol. 2013, 9, 154-163.
3. Majithia, V.; Geraci, S.A. Rheumatoid arthritis: Diagnosis and management. Am. J. Med. 2007, 120, 936-939.
4. Smolen, J.S.; Aletaha, D.; Koeller, M.; Weisman, M.H.; Emery, P. New therapies for treatment of rheumatoid arthritis. Lancet 2007, 370, 1861-1874.
5. Narváez, J.A.; Narváez, J.; de Lama, E.; de Albert, M. MR imaging of early rheumatoid arthritis. RadioGraphics 2010, 30, 143-163.
6. Lin, M.M.; Kim, D.K.; Haj, A.J.E.; Dobson, J. Development of superparamagnetic iron oxide nanoparticles (SPIONS) for translation to clinical applications. IEEE Trans. Nanobiosci. 2008, 7, 298-305.
7. Cutolo, M.; Sulli, A.; Pizzorni, C. Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann. Rheum. Dis. 2001, 60, 729-735.
8. Moura, C.C.; Segundo, M.A.; Neves, J.; Reis, S.; Sarmento, B. Co-association of methotrexate and SPIONs into anti-CD64 antibody-conjugated PLGA nanoparticles for theranostic application. Int. J. Nanomed. 2014, 9, 4911-4922.
9. Mashaghi, S.; Jadidi, T.; Koenderink, G.; Mashaghi, A. Lipid nanotechnology. Int. J Mol. Sci. 2013, 14, 4242-4282.
10. Sehgal, R. Nanotechnology and its applications in drug delivery: A review. Int. J. Med. Mol. Med. 2013, 3, WMC002867.
11. Coco, R.; Plapied, L.; Pourcelle, V.; Jerome, C.; Brayden, D.J.; Schneider, Y.J.; Preat, V. Drug delivery to inflamed colon by nanoparticles: Comparison of different strategies. Int. J. Pharm. 2013, 440, 3-12.
12. Couvreur, P. Nanoparticles in drug delivery: Past, present and future. Adv. Drug Deliv. Rev. 2013, 65, 21-23.
13. Mussi, S.V.; Sawant, R.; Perche, F.; Oliveira, M.C.; Azevedo, R.B.; Ferreira, L.A.; Torchilin, V.P. Novel nanostructured lipid carrier co-loaded with doxorubicin and docosahexaenoic acid demonstrates enhanced in vitro activity and overcomes drug resistance in MCF-7/Adr cells. Pharm. Res. 2014, 31, 1882-1892.
14. Venishetty, V.K.; Chede, R.; Komuravelli, R.; Adepu, L.; Sistla, R.; Diwan, P.V. Design and evaluation of polymer coated carvedilol loaded solid lipid nanoparticles to improve the oral bioavailability: A novel strategy to avoid intraduodenal administration. Colloids Surf. B Biointerfaces 2012, 95, 1-9.
15. Iqbal, M.A.; Md, S.; Sahni, J.K.; Baboota, S.; Dang, S.; Ali, J. Nanostructured lipid carriers system: Recent advances in drug delivery. J. Drug Target. 2012, 20, 813-830.
16. Sibeko, B.; Choonara, Y.E.; du Toit, L.C.; Modi, G.; Naidoo, D.; Khan, R.A.; Kumar, P.; Ndesendo, V.M.; Iyuke, S.E.; Pillay, V. Composite polylactic-methacrylic Acid copolymer nanoparticles for the delivery of methotrexate. J. Drug Deliv. 2012, doi:10.1155/2012/579629.
17. Zhang, Z.H.; Zhang, Y.L.; Zhou, J.P.; Lv, H.X. Solid lipid nanoparticles modified with stearic acid-octaarginine for oral administration of insulin. Int. J. Nanomed. 2012, 7, 3333-3339.
18. Patil, S.M.; Hemant, P.; Joshi, H.P. Lipid shell modified with combination of lipid and phospholipids in solid lipid nanoparticles for engineered specificity of paclitaxel in tumor bearing mice. Int. J. Drug Deliv. 2013, 5, 196-205.
19. Sapsford, K.E.; Algar, W.R.; Berti, L.; Gemmill, K.B.; Casey, B.J.; Oh, E.; Stewart, M.H.; Medintz, I.L. Functionalizing nanoparticles with biological molecules: Developing chemistries that facilitate nanotechnology. Chem. Rev. 2013, 113, 1904-2074.
20. Pan, H.; Myerson, J.W.; Hu, L.; Marsh, J.N.; Hou, K.; Scott, M.J.; Allen, J.S.; Hu, G.; San Roman, S.; Lanza, G.M.; et al. Programmable nanoparticle functionalization for in vivo targeting. FASEB J. 2013, 27, 255-264.
21. Duangjit, S.; Pamornpathomkul, B.; Opanasopit, P.; Rojanarata, T.; Obata, Y.; Takayama, K.; Ngawhirunpat, T. Role of the charge, carbon chain length, and content of surfactant on the skin penetration of meloxicam-loaded liposomes. Int. J. Nanomed. 2014, 9, 2005-2017.
22. Sussman, E.M.; Jayagopal, A.; Haselton, F.R.; Shastri, V.P. Engineering of solid lipid nanoparticles for biomedical applications. In New Delivery Systems for Controlled Drug Release from Naturally Occurring Materials; Parris, N., Liu, L., Song, C., Shastri, V.P., Eds.; American Chemical Society: Washington, DC, USA, 2008; Volume 992, pp. 139-152.
23. Sperling, R.A.; Parak, W.J. Surface modification, functionalization and bioconjugation of colloidal inorganic nanoparticles. Philos. Trans. Ser. A 2010, 368, 1333-1383.
24. Scholer, N.; Hahn, H.; Muller, R.H.; Liesenfeld, O. Effect of lipid matrix and size of solid lipid nanoparticles (SLN) on the viability and cytokine production of macrophages. Int. J. Pharm. 2002, 231, 167-176.
25. Martins, S.; Tho, I.; Reimold, I.; Fricker, G.; Souto, E.; Ferreira, D.; Brandl, M. Brain delivery of camptothecin by means of solid lipid nanoparticles: Formulation design, in vitro and in vivo studies. Int. J. Pharm. 2012, 439, 49-62.
26. Block, I.A. Particle Sizing by 3D Cross-correlation DLS in Highly Scattering Samples; LS Instruments: Fribourg, Switzerland, 2010.
27. Ekambaram, P.; Satahali, A.A.H.; Priyanka, K. Solid lipid nanoparticles: Review. Sci. Rev. Chem. Commun. 2012, 2, 80-102.
28. Raamsdonk, M.; Mei, H.C.; Soet, J.J.; Busscher, H.J.; Graaff, J. Effect of Polyclonal and Monoclonal antibodies on Surface properties of Streptococcus Sobrinus. Infect. Immun. 1995, 63, 1698-1702.
29. Shukla, N.; Liu, C.; Jones, P.M.; Weller, D. FTIR study of surfactant bonding to FePt nanoparticles. J. Magn. Magn. Mater. 2003, 266, 178-184.
30. Kato, Y.; Yamazaki, H.; Tomozawa, M. Detection of phase separation by ftir in a liquid-crystal-display substrate aluminoborosilicate glass. J. Am. Ceram. Soc. 2001, 84, 2111-2116.
31. Weyhers, H.; Ehlers, S.; Hahn, H.; Souto, E.B.; Muller, R.H. Solid Lipid Nanoparticles (SLN)-Effects of lipid composition on in vitro degradation and in vivo toxicity. Pharmazie 2006, 61, 539-544.
32. Widemann, B.C.; Adamson, P.C. Understanding and managing methotrexate nephrotoxicity. Oncologist 2006, 11, 694-703.
33. Houngbossa, K.; Guenzet, J.; Bourin, M. Effets de la température et du pH sur la cinétique de dissolution du méthotrexato en milieu aqueux. Ann. Pharm. Fr. 1996, 54, 77-84.